Effects of intranasal administration of recombinant murine interferon- γ on murine acute myocarditis caused by encephalomyocarditis virus

Circulation

Volumn 97, Issue 10, 1998, Pages 1017-1023

  Yamamoto, Norimi ^a   Shibamori, Masafumi ^b   Ogura, Motohiro ^b   Seko, Yoshinon ^b   Kikuchi, Mikio ^b  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b NONE

Author keywords

Cardiomyopathy; Immunology; Myocarditis; Viruses

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; RECOMBINANT GAMMA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENCEPHALOMYOCARDITIS VIRUS; HEART MUSCLE NECROSIS; HISTOPATHOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS MYOCARDITIS;

EID: 0032539844     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.10.1017     Document Type: Article

References (20)

1. Matsumori A, Kawai C. An animal model of congestive (dilated) cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus. Circulation. 1982;66:355-360.
2. Kanda T, Nagaoka H, Kaneko K, Wilson JE, McManus BM, Imai S, Suzuki T, Murata K, Kobayashi I. Synergistic effects of tacrolimus and human interferon-a A/D in murine viral myocarditis. J Pharmacol Exp Ther. 1995;274:487-493.
3. Gresser I, Tovey MG, Bandu M, Maury C, Brouty-Boye D. Role of inerferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum, I: rapid evolution of encephalomyocarditis virus infection. J Exp Med. 1976;144:1305-1315.
4. Weck PK, Rinderknecht E, Estell DA, Stebbing N. Antiviral activity of bacteria-derived human alpha interferons against encephalomyocarditis virus infection of mice. Infect Immun. 1982;35:660-665.
5. Connel EV, Cerruti RL, Sim IS. Interactions between recombinant interferons alpha and gamma in the treatment of experimental virus infections in mice. In: Stewart WE, Schellekens H, eds. The Biology of the Interferon System 1985. Amsterdam: Elsevier Science Publishers BV; 1986:419-422.
6. Matsumori A, Crumpacker CS, Abelmann WH. Prevention of viral myocarditis with recombinant human leukocyte interferon α A/D in murine model. J Am Coll Cordiol. 1987;9:1320-1325.
7. Shalaby MR, Hamilton EB, Benninger AH, Marafino BJ. In vivo antiviral activity of recombinant murine gamma interferon. J Interferon Res. 1985;5:339-345.
8. Iida J, Saiki I, Ishihara C, Azuma I. Protective activity of recombinant cytokines against Sendai virus and herpes simplex virus (HSV) infection in mice. Vaccine. 1989;7:229-233.
9. Schanker LS. Drug absorption from the lung. Biochem Pharmacol. 1978;27:381-385.
10. Schanker LS, Mitchell EW, Brown RA Jr. Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection. Drug Metab Dispos. 1986;14:79-88.
11. Patton JS, Trinchero P, Platz RM. Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid hormones. J Control Releas. 1994;28:79-85.
12. Rubin BY, Gupta SL. Differential efficacies of human type I and II interferons as antiviral and antiproliferative agents. Proc Natl Acad Sci U S A. 1980;77:5928-5932.
13. Johnson HM, Bazer FW, Szente BE, Jarpe MA. How interferons fight disease. Sci Am. 1994;270:40-47.
14. Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kamijo R, Vilček J, Zinkernagel RM, Ague M. Immune response in mice that lack the interferon-γ receptor. Science. 1993;259:1742-1745.
15. Kamijo R, Shapiro D, Le J, Huang S, Aguet M, Vilček J. Generation of nitric oxide and induction of major histocompatibility complex class II. Proc Natl Acad Sci U S A. 1993;90:6626-6630.
16. Seko Y, Takahashi N, Yagita H, Okumura K, Yazaki Y. Expression of cytokine mRNAs in murine hearts with acute myocarditis caused by coxsackievirus B3. J Pathol. 1997;183:105-108.
17. Seko Y, Matsuda H, Kato K, Hashimoto Y, Yagita H, Okumura K, Yazaki Y. Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3. J Clin Invest. 1993;91:1327-1336.
18. Godeny EK, Gauntt CJ. Murine natural killer cells limit coxsackievirus B3 replication. J Immunol. 1987;139:913-918.
19. Siegener MS, Heim A, Figulla HR. Subclassification of dilated cardiomyopathy and interferon treatment. Eur Heart J. 1995;16(suppl O):147-149.
20. Mirić M, Mišković A, Vasiljević JD, Keserović N, Pešić M. Interferon and thymic hormones in the therapy of human myocarditis and idiopathic dilated cardiomyopathy. Eur Heart J. 1995;16(suppl O):150-152.